Results 281 to 290 of about 3,474,333 (323)
Some of the next articles are maybe not open access.
A phase 1 study evaluating ABT-414 in combination with temozolomide (TMZ) for subjects with recurrent or unresectable glioblastoma (GBM).
, 2014 H. Gan, L. Fichtel, A. Lassman, R. Merrell, M. J. van den Bent, P. Kumthekar, A. Scott, M. Pedersen, E. Gomez, J. Fischer, W. Ames, H. Xiong, M. Dudley, W. Munasinghe, L. Roberts-Rapp, P. Ansell, K. Holen, D. Reardon +17 moresemanticscholar +1 more sourcePhase I study of ABT-414 mono- or combination therapy with temozolomide (TMZ) in recurrent glioblastoma (GBM).
, 2015 H. Gan, K. Papadopoulos, L. Fichtel, A. Lassman, R. Merrell, M. Bent, P. Kumthekar, A. Scott, M. Pedersen, E. Gomez, J. Fischer, W. Ames, H. Xiong, Ho-Jin Lee, W. Munasinghe, L. Roberts-Rapp, P. Ansell, K. Holen, R. Lai, D. Reardon +19 moresemanticscholar +1 more sourceAbstract 2506: A phase 1 study of ABT-806, a humanized recombinant anti-EGFR monoclonal antibody, in patients with advanced solid tumors
, 2012 J. Cleary, L. Yee, N. Azad, M. Carducci, D. Cosgrove, S. Limaye, L. Gandhi, M. Pedersen, P. Ansell, W. Ames, Shringi Sharma, Y. Hsu, W. Munasinghe, E. Reilly, K. Holen, R. Humerickhouse +15 moresemanticscholar +1 more sourceABT-414 in patients with advanced solid tumors likely to overexpress the epidermal growth factor receptor (EGFR).
, 2015 G. Goss, E. Vokes, M. Gordon, L. Gandhi, K. Papadopoulos, D. Rasco, M. Pedersen, J. Fischer, K. Chu, W. Ames, H. Xiong, Ho-Jin Lee, J. Zeng, L. Roberts-Rapp, P. Ansell, E. Reilly, K. Holen, A. Tolcher +17 moresemanticscholar +1 more source342 A phase 1/2 study evaluating the safety, pharmacokinetics and efficacy of ABT-414 in subjects with advanced solid tumors likely to over-express the epidermal growth factor receptor (EGFR)
, 2014 A. Tolcher, G. Goss, M. Gordon, L. Gandhi, K. Papadopoulos, D. Rasco, M. Pedersen, J. Fischer, W. Ames, H. Xiong, M. Dudley, W. Munasinghe, P. Ansell, K. Holen, E. Vokes +14 moresemanticscholar +1 more source